Literature DB >> 24452634

Utilization of FibroScan in clinical practice.

Alan Bonder1, Nezam Afdhal.   

Abstract

The evaluation of liver fibrosis is critical, particularly to rule out cirrhosis. Novel non-invasive tests such as transient ultrasound elastography are widely used to stage liver fibrosis as an alternative to liver biopsy, and this technology has recently been approved in the US. In this review, we discuss the performance characteristics of elastography for a variety of liver diseases and highlight practical appropriate suggestions for how to incorporate this technology into clinical practice.

Entities:  

Mesh：

Year:  2014        PMID： 24452634     DOI： 10.1007/s11894-014-0372-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  36 in total

1.  Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.

Authors:  Elliot B Tapper; Eric B Cohen; Keyur Patel; Bruce Bacon; Stuart Gordon; Eric Lawitz; David Nelson; Imad A Nasser; Tracy Challies; Nezam Afdhal
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-28       Impact factor: 11.382

2.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.

Authors:  Christophe Corpechot; Ahmed El Naggar; Armelle Poujol-Robert; Marianne Ziol; Dominique Wendum; Olivier Chazouillères; Victor de Lédinghen; Daniel Dhumeaux; Patrick Marcellin; Michel Beaugrand; Raoul Poupon
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific.

Authors:  S Pritchett; A Cardenas; D Manning; M Curry; N H Afdhal
Journal:  J Viral Hepat       Date:  2010-10-07       Impact factor: 3.728

4.  Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C.

Authors:  Naveen Gara; Xiongce Zhao; David E Kleiner; T Jake Liang; Jay H Hoofnagle; Marc G Ghany
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-07       Impact factor: 11.382

5.  Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.

Authors:  Naim Alkhouri; Emad Sedki; Anna Alisi; Rocio Lopez; Massimo Pinzani; Ariel E Feldstein; Valerio Nobili
Journal:  Liver Int       Date:  2012-11-12       Impact factor: 5.828

6.  Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography.

Authors:  Agostino Colli; Pietro Pozzoni; Alessandra Berzuini; Alessandro Gerosa; Cristina Canovi; Edoardo Ennio Molteni; Marco Barbarini; Ferruccio Bonino; Daniele Prati
Journal:  Radiology       Date:  2010-10-08       Impact factor: 11.105

7.  Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.

Authors:  Vincent Wai-Sun Wong; Julien Vergniol; Grace Lai-Hung Wong; Juliette Foucher; Anthony Wing-Hung Chan; Faiza Chermak; Paul Cheung-Lung Choi; Wassil Merrouche; Shirley Ho-Ting Chu; Sophie Pesque; Henry Lik-Yuen Chan; Victor de Lédinghen
Journal:  Am J Gastroenterol       Date:  2012-10-02       Impact factor: 10.864

8.  Hepatitis C and progression of HIV disease.

Authors:  Mark S Sulkowski; Richard D Moore; Shruti H Mehta; Richard E Chaisson; David L Thomas
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease.

Authors:  C Bureau; S Metivier; J M Peron; J Selves; M A Robic; P A Gourraud; O Rouquet; E Dupuis; L Alric; J P Vinel
Journal:  Aliment Pharmacol Ther       Date:  2008-04-04       Impact factor: 8.171

10.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998
View more
  32 in total

1.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Authors:  Harel Dahari; Laetitia Canini; Frederik Graw; Susan L Uprichard; Evaldo S A Araújo; Guillaume Penaranda; Emilie Coquet; Laurent Chiche; Aurelie Riso; Christophe Renou; Marc Bourliere; Scott J Cotler; Philippe Halfon
Journal:  J Hepatol       Date:  2016-02-22       Impact factor: 25.083

2.  Editorial: A New Spin on Magnetic Resonance Elastography.

Authors:  Rekha Kishore; Rohit Loomba; Richard K Sterling
Journal:  Am J Gastroenterol       Date:  2016-06       Impact factor: 10.864

3.  Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.

Authors:  Jennifer B Lai; Maxwell A Witt; Mary Patricia Pauly; Joanna Ready; Michael Allerton; Suk Seo; David J Witt
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?

Authors:  James H Lewis
Journal:  Dig Dis Sci       Date:  2014-08       Impact factor: 3.199

Review 5.  Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.

Authors:  Dharmesh H Kaswala; Michelle Lai; Nezam H Afdhal
Journal:  Dig Dis Sci       Date:  2016-03-26       Impact factor: 3.199

6.  No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Patricia Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-11       Impact factor: 11.382

7.  Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic.

Authors:  Vijay Pandyarajan; Robert G Gish; Naim Alkhouri; Mazen Noureddin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-07

8.  Utility of evaluating HCV in an uninsured population.

Authors:  Indira Donepudi; Angelo Paredes; Sarah Hubbard; Chadi Awad; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2014-11-05       Impact factor: 3.199

Review 9.  Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy.

Authors:  Cristiane Valle Tovo; Angelo Zambam de Mattos; Gabriela Perdomo Coral; Fernanda Schild Branco; Eiji Suwa; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 10.  Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis.

Authors:  K Thavorn; D Coyle
Journal:  Ont Health Technol Assess Ser       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.